Depo-Provera Lawsuits 2026: the Meningioma Science Behind the Claims — Do You Qualify?
Women who used the birth-control shot Depo-Provera for a year or more and were later diagnosed with a meningioma — a tumor of the membranes surrounding the brain — may have a legal claim. A March 2024 study in The BMJ linked prolonged use of the drug to roughly 5.6 times the risk of intracranial meningioma, and federal lawsuits are now consolidated in MDL No. 3140 in the Northern District of Florida.
Key facts
- Depo-Provera is depot medroxyprogesterone acetate (DMPA), an injectable contraceptive given roughly every 12 to 13 weeks.
- A March 2024 study in The BMJ reported that at least 12 months of medroxyprogesterone acetate use was associated with about 5.6 times the risk of intracranial meningioma.
- A meningioma is a tumor of the meninges — the protective membranes around the brain and spinal cord — and often requires brain surgery.
- Federal Depo-Provera cases are centralized as MDL No. 3140 in the U.S. District Court for the Northern District of Florida.
- Compensation varies widely by case, and most settlements in product-liability litigation are confidential.
What Depo-Provera actually is
Depo-Provera is the brand name for depot medroxyprogesterone acetate, or DMPA — a progestin-only birth-control injection administered into the muscle about once every three months. It prevents pregnancy mainly by suppressing ovulation, and it has been prescribed for decades to women who prefer not to take a daily pill. Millions of women worldwide have used it, many of them continuously for years.
The 2024 BMJ study that changed everything
In March 2024, researchers led by Noémie Roland published a study in The BMJ using data from the French national health system. The finding that reshaped the legal landscape: women who had used medroxyprogesterone acetate for 12 months or longer faced approximately 5.6 times the risk of developing an intracranial meningioma compared with non-users. The risk appeared to grow with longer cumulative use, which is precisely the pattern plaintiff attorneys look for — a dose-response relationship. Notably, the study did not find the same association for other hormonal contraceptives it examined.
What a meningioma is — and why the diagnosis is serious
A meningioma is a tumor that arises from the meninges, the three protective membranes enveloping the brain and spinal cord. Most meningiomas are classified as benign, meaning they do not spread through the body the way malignant cancers do — but "benign" is misleading here. Inside the skull there is no room to spare, so even a slow-growing meningioma can press on the brain, causing chronic headaches, vision changes, seizures, memory problems, or weakness. Treatment frequently means craniotomy — brain surgery — and sometimes radiation. For the women in these lawsuits, a routine contraceptive choice led, years later, to a neurosurgeon's operating table.
Who is filing Depo-Provera lawsuits in 2026
The core group in the litigation consists of women who received Depo-Provera injections over an extended period — typically a year or more — and were subsequently diagnosed with a meningioma, often intracranial, that required surgery or other significant treatment. Some plaintiffs used the shot for contraception; others received it for medical reasons such as endometriosis. What unites the claims is the allegation that the manufacturers knew or should have known about the meningioma risk and failed to warn patients and doctors adequately.
The qualification checklist lawyers use
No attorney can promise you qualify without reviewing your records, but firms evaluating Depo-Provera cases generally look for four elements. First, documented use of Depo-Provera or its generic equivalents — pharmacy or clinic records showing repeated injections over at least a year. Second, a confirmed meningioma diagnosis, typically intracranial, supported by imaging and pathology. Third, meaningful harm: brain surgery, radiation, lasting neurological injury, or substantial medical costs. Fourth, a filing deadline that has not yet passed. If you are missing any piece, gather what you can — records can often be obtained from your pharmacy and imaging center.
MDL 3140: where the cases stand
Depo-Provera lawsuits filed in federal court have been centralized in multidistrict litigation — MDL No. 3140 — before the U.S. District Court for the Northern District of Florida. An MDL is a procedural device that groups similar cases before one judge for pretrial proceedings: shared discovery, expert reports, and bellwether trial selection. It is not a class action; each plaintiff keeps an individual case and an individual result. Cases in the MDL remain in early phases, with discovery and expert work ongoing — there is no confirmed global settlement, and any figures circulating online about payouts are speculation. For plain-language breakdowns of complex cases like this one, see the Problem Solved channel: https://www.youtube.com/@problemsolved-x3m.
Deadlines: the statute of limitations matters more than the science
A statute of limitations is the legal deadline for filing a lawsuit, and it varies by state — commonly one to three years for injury claims, though some states allow longer. Many states apply a discovery rule, meaning the clock may start when you reasonably learned (or should have learned) that the drug caused your tumor, not the date of the injection. But these rules are technical, fact-specific, and unforgiving: miss the deadline and the claim is gone regardless of its strength. If you were diagnosed with a meningioma after prolonged Depo-Provera use, do not wait for the litigation to develop — get a legal evaluation promptly.
What to do if you think you have a claim
Start by collecting your records: pharmacy printouts showing Depo-Provera prescriptions, clinic notes, MRI or CT reports, pathology results, and surgical records. Write down a timeline of your injections and your diagnosis. Then consult a firm handling the Depo-Provera MDL — most take these cases on a contingency basis, meaning no upfront fee and payment only from a recovery. Bring your records to the consultation so the evaluation is based on documents, not memory. Related reading: our guide to Depo-Provera lawsuit deadlines and who qualifies, the hernia mesh lawsuit qualification guide, and the Suboxone tooth-decay lawsuit overview.
This article provides general information about the Depo-Provera litigation. It is not legal or medical advice. Consult a qualified attorney in your state about your situation.
Who Benefits From This — and Who Does Not
Women with a year or more of documented use and a confirmed meningioma. If pharmacy or clinic records show Depo-Provera injections over at least a year, and imaging and pathology confirm an intracranial meningioma that required surgery, radiation, or other significant treatment, you match the core group of this litigation: the first step is to gather the pharmacy records and the imaging and pathology reports.
Women treated for medical reasons, not only contraception. Some plaintiffs received the shot for endometriosis or other medical reasons rather than contraception; what unites the claims is the allegation that the manufacturers knew or should have known about the meningioma risk and failed to warn adequately.
Who does not benefit. Without a confirmed meningioma diagnosis, or without documented use, there is no claim to evaluate — and attorneys focus on a year or more of use, since the March 2024 BMJ study identified the elevated risk at 12 months or more. Once the filing deadline has passed, even a strong medical file cannot proceed. And no confirmed global settlement exists: any payout figures circulating online are speculation. A related drug case is explained in our guide to Leqembi and Kisunla lawsuits.
Frequently asked questions
What is the Depo-Provera lawsuit about?
Plaintiffs allege that prolonged use of Depo-Provera (medroxyprogesterone acetate) increased their risk of meningioma brain tumors and that manufacturers failed to warn of that risk. Federal cases are consolidated in MDL No. 3140 in the Northern District of Florida.
How long did you have to use Depo-Provera to qualify?
The March 2024 BMJ study identified the elevated meningioma risk at 12 months or more of use, and attorneys generally focus on women with a year or more of documented injections — though each case is evaluated individually.
What did the BMJ study actually find?
Using French national health data, researchers reported that at least 12 months of medroxyprogesterone acetate use was associated with roughly 5.6 times the risk of intracranial meningioma, with risk rising alongside cumulative exposure.
Is there a Depo-Provera settlement yet?
No confirmed global settlement exists. The MDL remains in pretrial phases, and most settlements in mass-tort litigation are confidential — treat any payout figures you see online as unverified.
How much does it cost to hire a Depo-Provera lawyer?
Most firms handling these cases work on contingency, so there is no upfront fee; the firm is paid from any recovery. Ask for the fee agreement in writing before signing.
Who benefits from this guide, and how do I start?
The guide benefits women with a year or more of documented Depo-Provera injections who were later diagnosed with a confirmed, typically intracranial, meningioma that caused meaningful harm — brain surgery, radiation, lasting neurological injury, or substantial medical costs. Start here: gather pharmacy or clinic records showing repeated injections over at least a year, the imaging and pathology confirming the diagnosis, and records of treatment — then have the filing deadline checked, since it matters more than the science once it passes.